BioCryst
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
4505 Emperor Blvd Ste 200, Durham, North...Phone Number
(919) 859-1302Website
www.biocryst.comRevenue
$885.7 MillionStock Symbol
BCRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
5
1
2
1
1
About BioCryst
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.Explore more
BioCryst Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCryst your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at BioCryst
Check if BioCryst has recently received funding, and reach out quickly before it becomes old news!
Click to see if BioCryst had a recent Job posting/layoffs
BioCryst, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BioCryst is spiking on competitors!
Funding: Get notified immidiatlly once BioCryst has new funding data
Product Launch: Get notified when BioCryst launches new products
Earning: See what the market has to say on BioCryst recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to BioCryst
Compare insights from companies similar to BioCryst, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$673M
1K - 5K
Public
$1.6B
2010
AM
Alyssa MooreChief of Staff and Head Senior Vice President, Program and Portfolio Management
Company Profile Activity
Activity Insights
BioCryst is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioCryst is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioCryst.
BioCryst financials insights
Gather financial insights about BioCryst, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$4.1M
Grant
$2.4M
2016
Debt
$23M
2018
Grant
$3.5M
2019
Debt
$100M
Stock Offering
$63M
2021
Other Financing Round
$350M
2023
Debt
$450M
BioCryst Tech Stack
A closer look at the technologies used by BioCryst
See more technologies
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings, Acquisitions, Finance
Person-Based
Earnings, Financial Reporting, Finance
Person-Based
Earnings, Acquisitions, Finance
BioCryst News & Media
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibartBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Turkey, from June 12-15, 2026.BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026.BioCryst Pharmaceuticals Q1 Earnings Call Highlights
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its development pipeline, while also flagging a manufacturing issue that will delay initial fulfillment
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioCryst
Sign Up For FreeTo access detailed company insights
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.... Read More
